Literature DB >> 25277787

Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.

Sang-Yong Shin1, Seung-Tae Lee1, Hee-Jin Kim1, Suk Jin Kim2, Kihyun Kim2, Eun Suk Kang1, Sun-Hee Kim1.   

Abstract

BACKGROUND: Immunophenotyping of plasma cell has become an important diagnostic tool for plasma cell myeloma. There have been a few studies for association of antigen expression and cytogenetic abnormality of plasma cell myeloma.
METHODS: A total of 68 symptomatic/smoldering plasma cell myeloma case were analyzed by multicolor flow cytometry using CD38 and CD138 for primary gating of plasma cells. A conventional cytogenetics and fluorescence in situ hybridization (FISH) studies for detection of del(13q) or aneuploidy, del(17p), and IGH/FGFR translocation were done. We statistically analyzed the association of antigen expression and cytogenetic abnormality/myeloma stage (international staging system for multiple myeloma).
RESULTS: Positive expression of CD19, CD28, CD45, CD56, CD117, and CD274 was detected in 8.8%, 50.0%, 50.0%, 75.0%, 39.7%, and 2.9% of cases, respectively. CD117-negative cases were associated with hypodiploidy (P = 0.017). CD45-negative cases were associated with deletion 13 or aneuploidy (P < 0.001) and del(17p)(P = 0.011) by FISH. CD45-negativity or CD117-negativity was associated with advanced stage (P = 0.012 and P = 0.016, respectively).
CONCLUSION: The antigen expression patterns of myeloma plasma cell were associated with cytogenetic abnormality and stage.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  cytogenetic abnormality; flow-cytometry; myeloma

Mesh:

Substances:

Year:  2014        PMID: 25277787      PMCID: PMC6806724          DOI: 10.1002/jcla.21801

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  27 in total

1.  Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.

Authors:  Hong Chang; Sara Samiee; Qi Long Yi
Journal:  Leuk Lymphoma       Date:  2006-01

2.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

3.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

Review 4.  The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.

Authors:  Jeffrey R Sawyer
Journal:  Cancer Genet       Date:  2011-01

5.  Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Authors:  Hervé Avet-Loiseau; Cyrille Hulin; Loic Campion; Philippe Rodon; Gerald Marit; Michel Attal; Bruno Royer; Mamoun Dib; Laurent Voillat; Didier Bouscary; Denis Caillot; Marc Wetterwald; Brigitte Pegourie; Gerard Lepeu; Bernadette Corront; Lionel Karlin; Anne-Marie Stoppa; Jean-Gabriel Fuzibet; Xavier Delbrel; Francois Guilhot; Brigitte Kolb; Olivier Decaux; Thierry Lamy; Laurent Garderet; Olivier Allangba; Francois Lifermann; Bruno Anglaret; Philippe Moreau; Jean-Luc Harousseau; Thierry Facon
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

6.  Genetic abnormalities and patterns of antigenic expression in multiple myeloma.

Authors:  Gema Mateo; Mariana Castellanos; Ana Rasillo; Norma C Gutiérrez; Ma Angeles Montalbán; Ma Luisa Martín; Jesús Ma Hernández; Ma Consuelo López-Berges; Laura Montejano; Joan Bladé; Ma Victoria Mateos; Anna Sureda; Javier de la Rubia; Joaquín Díaz-Mediavilla; Atanasio Pandiella; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

7.  Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).

Authors:  M Hundemer; U Klein; D Hose; M-S Raab; F W Cremer; A Jauch; A Benner; C Heiss; M Moos; A D Ho; H Goldschmidt
Journal:  Bone Marrow Transplant       Date:  2007-09-24       Impact factor: 5.483

8.  Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.

Authors:  L- J Chen; J- Y Li; W Xu; H- R Qiu; Y Zhu; Y- P Zhang; L- M Duan; S- X Qian; H Lu
Journal:  Exp Oncol       Date:  2007-06

9.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Authors:  Andy C Rawstron; Alberto Orfao; Meral Beksac; Ludmila Bezdickova; Rik A Brooimans; Horia Bumbea; Klara Dalva; Gwenny Fuhler; Jan Gratama; Dirk Hose; Lucie Kovarova; Michael Lioznov; Gema Mateo; Ricardo Morilla; Anne K Mylin; Paola Omedé; Catherine Pellat-Deceunynck; Martin Perez Andres; Maria Petrucci; Marina Ruggeri; Grzegorz Rymkiewicz; Alexander Schmitz; Martin Schreder; Carine Seynaeve; Martin Spacek; Ruth M de Tute; Els Van Valckenborgh; Nicky Weston-Bell; Roger G Owen; Jesús F San Miguel; Pieter Sonneveld; Hans E Johnsen
Journal:  Haematologica       Date:  2008-02-11       Impact factor: 9.941

10.  Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.

Authors:  Naohi Sahara; Akihiro Takeshita; Kazuyuki Shigeno; Shinya Fujisawa; Kaori Takeshita; Kensuke Naito; Michio Ihara; Takaaki Ono; Sadahiro Tamashima; Kenji Nara; Kazunori Ohnishi; Ryuzo Ohno
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

View more
  2 in total

1.  The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients.

Authors:  Funda Ceran; Mesude Falay; Simten Dağdaş; Gülsüm Özet
Journal:  Turk J Haematol       Date:  2017-03-08       Impact factor: 1.831

2.  Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization.

Authors:  Ying Hu; Wenming Chen; Shilun Chen; Zhongxia Huang
Journal:  Onco Targets Ther       Date:  2016-03-03       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.